Ⅱ-2. 乳癌領域
Ⅱ-3. 卵巣癌領域
Ⅱ-4. 前立腺癌領域
Ⅱ-5. 膵癌領域
| 新CQ番号 | 検索式 | 検索DB |
|---|---|---|
| CQ1,CQ2 | (BRCA*[TW] OR hereditary breast[TW] OR ((heredit*[TW] OR inherit*[TW] OR genet*[TW] OR familial*[TW] OR mutat*[TW]) AND (breast cancer[TW] OR Breast Neoplasms[MeSH]))) AND ((mastectomy[TW]) OR (surgery[TW])) AND ((risk-reducing[TW]) OR (prophylactic[TW]) OR (CRRM[TW])) AND (English[LA] OR Japanese[LA]) AND 2020[DP]:202303[DP] | PubMed |
| MeSH descriptor: [Breast Neoplasms] explode all trees (breast):ti,ab,kw (cancer OR carcinoma OR tumor OR tumour):ti,ab,kw #3 AND #4 #2 OR #5 #1 AND #6 (mastectomy OR CRRM OR BRRM):ti,ab,kw #7 AND #8 #9 with Cochrane Library publication date Between Jan 2020 and Mar 2023, in Cochrane Reviews #9 with Publication Year from 2019 to 2023, in Trials | Cochrane | |
| ((((((((((遺伝性乳癌卵巣癌症候群/TH) or (((乳房腫瘍/TH or 乳癌/AL)) and ((遺伝性/AL) or (HBOC/AL) or (BRCA/AL)))) and ((乳房切除術/TH or 乳房切除/AL or RRM/AL)))) and (PT=会議録除く))) and (DT=2020:2023))) and (CK=ヒト))) | 医中誌 | |
| CQ3 | ((BRCA*[TW] OR hereditary breast[TW] OR ((heredit*[TW] OR inherit*[TW] OR genet*[TW] OR familial*[TW] OR mutat*[TW]) AND (breast cancer[TW] OR Breast Neoplasms[MeSH]))) AND ((“Mastectomy, Segmental”[Mesh]) OR ((conserv*[TW]) AND (surgery[TW])))) AND (English[LA] OR Japanese[LA]) AND 2020[DP] : 2023/03[DP] | PubMed |
| #1 (BRCA OR heredit* OR inherit* OR genet* OR familial* OR mutat*):ti,ab,kw #2 MeSH descriptor: [Breast Neoplasms] explode all trees #3 (breast):ti,ab,kw #4 (cancer OR carcinoma OR tumor OR tumour):ti,ab,kw #5 #3 AND #4 #6 #2 OR #5 #7 #1 AND #6 #8 (conserv* OR segmental):ti,ab,kw #9 #7 AND #8 #10 #9 with Cochrane Library publication date Between Jan 2020 and Mar 2023, in Cochrane Reviews #11 #9 with Publication Year from 2019 to 2023, in Trials | Cochrane | |
| ((((遺伝性乳癌卵巣癌症候群/TH) or (((乳房腫瘍/TH or 乳癌/AL)) and ((遺伝性/AL) or (HBOC/AL) or (BRCA/AL)))) and ((乳房温存/AL) or ([乳房温存療法]/TH)))) and (DT=2020:2023 and PT=会議録除く) | 医中誌 | |
| CQ4 | ((((BRCA*[TW] OR hereditary breast[TW] OR ((heredit*[TW] OR inherit*[TW] OR genet*[TW] OR familial*[TW] OR mutat*[TW]) AND (breast cancer[TW] OR Breast Neoplasms[MeSH]))) AND ((diagnostic imaging[SH]) OR (“Diagnostic Imaging”[Mesh])) AND ((surveillance[TW] OR screening[TW]) OR (“Early Diagnosis”[Mesh]))) AND ((risk[TW]) OR (sensitiv*[TW] OR sensitivity and specificity[MeSH]))) AND (English[LA] OR Japanese[LA]) AND 2020[DP] : 2023/03[DP]) AND (“Breast Neoplasms”[Mesh] OR “breast cancer”[TW]) | PubMed |
| #1 (BRCA OR heredit* OR inherit* OR genet* OR familial* OR mutat*):ti,ab,kw #2 MeSH descriptor: [Breast Neoplasms] explode all trees #3 (breast):ti,ab,kw #4 (cancer OR carcinoma OR tumor OR tumour):ti,ab,kw #5 #3 AND #4 #6 #2 OR #5 #7 #1 AND #6 #8 (surveillance OR screening):ti,ab,kw #9 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees #10 (“magnetic resonance” OR MRI):ti,ab,kw #11 #9 OR #10 #12 #7 AND #8 AND #11 #13 #12 with Cochrane Library publication date Between Jan 2020 and Mar 2023, in Cochrane Reviews #14 #12 with Publication Year from 2019 to 2023, in Trials | Cochrane | |
| (((((遺伝性乳癌卵巣癌症候群/TH) or (((乳房腫瘍/TH or 乳癌/AL)) and ((遺伝性/AL) or (HBOC/AL) or (BRCA/AL)))) and (((集団サーベイランス/TH or サーベイランス/AL)) or ((集団検診/TH or スクリーニング/AL)) or ((MRI/TH or MRI/AL))))) and (DT=2020:2023 and PT=会議録除く)) and ((乳房腫瘍/TH) and (SH=画像診断,X線診断,放射性核種診断,超音波診断)) | 医中誌 | |
| CQ5 | (((BRCA*[TW] OR hereditary breast[TW] OR ((heredit*[TW] OR inherit*[TW] OR genet*[TW] OR familial*[TW] OR mutat*[TW]) AND (breast cancer[TW] OR Breast Neoplasms[MeSH]))) AND (tamoxifen[TW])) AND ((“Chemoprevention”[Mesh] OR chemoprevent*[TW]) OR (prevent*[TW]))) AND (English[LA] OR Japanese[LA]) AND 2020[DP] : 2023/03[DP] | PubMed |
| #1 (BRCA OR heredit* OR inherit* OR genet* OR familial* OR mutat*):ti,ab,kw #2 MeSH descriptor: [Breast Neoplasms] explode all trees #3 (breast):ti,ab,kw #4 (cancer OR carcinoma OR tumor OR tumour):ti,ab,kw #5 #3 AND #4 #6 #2 OR #5 #7 #1 AND #6 #8 (tamoxifen):ti,ab,kw #9 #7 AND #8 #10 #9 with Cochrane Library publication date Between Jan 2020 and Mar 2023, in Cochrane Reviews #11 #9 with Publication Year from 2019 to 2023, in Trials | Cochrane | |
| ((((遺伝性乳癌卵巣癌症候群/TH) or (((乳房腫瘍/TH or 乳癌/AL)) and ((遺伝性/AL) or (HBOC/AL) or (BRCA/AL)))) and ((化学予防/TH or 化学予防/AL or tamoxifen/AL or タモキシフェン/AL)))) and (DT=2020:2023 and PT=会議録除く) | 医中誌 | |
| CQ6 | ((BRCA*[TW] OR hereditary breast[TW] OR ((heredit*[tiab] OR inherit*[tiab] OR genet*[tiab] OR familial*[tiab] OR mutat*[tiab]) AND (breast cancer[tiab] OR Breast Neoplasms[MeSH]))) AND (“Platinum Compounds”[Mesh] OR platinum[TW] OR cisplatin[TW])) AND (advanced[TIAB] OR metastatic[TIAB] OR “Neoplasm Metastasis”[MH] OR “Neoplasm Recurrence, Local”[MH])) AND (English[LA] OR Japanese[LA]) AND 2020[DP] : 2023/03[DP] | PubMed |
| #1 (BRCA OR heredit* OR inherit* OR genet* OR familial* OR mutat*):ti,ab,kw #2 MeSH descriptor: [Breast Neoplasms] explode all trees #3 (breast):ti,ab,kw #4 (cancer OR carcinoma OR tumor OR tumour):ti,ab,kw #5 #3 AND #4 #6 #2 OR #5 #7 #1 AND #6 #8 (platinum):ti,ab,kw #9 (cisplatin):ti,ab,kw #10 #8 OR #9 #11 #7 AND #10 #12 advanced OR metasta* #13 #11 AND #12 #14 #13 with Cochrane Library publication date from Jan 2020 to present, in Cochrane Reviews #15 #13 with Publication Year from 2019 to 2023, in Trials | Cochrane | |
| ((((遺伝性乳癌卵巣癌症候群/TH) or (((乳房腫瘍/TH or 乳癌/AL)) and ((遺伝性/AL) or (HBOC/AL) or (BRCA/AL)))) and (((白金/TH or プラチナ/AL)) or (platinum/TA)))) and (DT=2020:2023 and PT=会議録除く) | 医中誌 | |
| CQ7 | ((BRCA*[TW] OR hereditary breast[TW] OR ((heredit*[tiab] OR inherit*[tiab] OR genet*[tiab] OR familial*[tiab] OR mutat*[tiab]) AND (breast cancer[tiab] OR Breast Neoplasms[MeSH]))) AND (“Poly(ADP-ribose) Polymerase Inhibitors”[Mesh] OR “Poly(ADP-ribose) Polymerase Inhibitors” [Pharmacological Action]) AND (advanced[TIAB] OR metastatic[TIAB] OR “Neoplasm Metastasis”[MH] OR “Neoplasm Recurrence, Local”[MH])) AND (English[LA] OR Japanese[LA]) AND 2020[DP] : 2023/03[DP] | PubMed |
| CQ7 | #1 (BRCA OR heredit* OR inherit* OR genet* OR familial* OR mutat*):ti,ab,kw #2 MeSH descriptor: [Breast Neoplasms] explode all trees #3 (breast):ti,ab,kw #4 (cancer OR carcinoma OR tumor OR tumour):ti,ab,kw #5 #3 AND #4 #6 #2 OR #5 #7 #1 AND #6 #8 advanced OR metasta* #9 #7 AND #8 #10 (Polymerase):ti,ab,kw OR PARP:ti,ab,kw #11 #9 AND #10 #12 #11 with Cochrane Library publication date from Jan 2020 to present, in Cochrane Reviews #13 #11 with Publication Year from 2019 to 2023, in Trials | Cochrane |
| CQ7 | ((((遺伝性乳癌卵巣癌症候群/TH) or (((乳房腫瘍/TH or 乳癌/AL)) and ((遺伝性/AL) or (HBOC/AL) or (BRCA/AL)))) and ((“Poly (ADP-Ribose) Polymerase-1″/TH) or (PARP/TA)))) and (DT=2020:2023 and PT=会議録除く) | 医中誌 |
| CQ8 | (“brca*”[Text Word] OR “hereditary breast”[Text Word] OR ((“heredit*”[Text Word] OR “inherit*”[Text Word] OR “genet*”[Text Word] OR “familial*”[Text Word] OR “mutat*”[Text Word]) AND (“breast cancer”[Text Word] OR “breast neoplasms”[MeSH Terms]))) AND (“poly adp ribose polymerase inhibitors”[MeSH Terms] OR “poly adp ribose polymerase inhibitors”[Pharmacological Action] OR “PARP”[Text Word]) AND (“neoadjuvant therapy”[MeSH Terms] OR “neoadjuvant”[Text Word]) AND (“English”[Language] OR “Japanese”[Language]) AND 2020/01/01:2023/03/31[Date – Publication] | PubMed |
| #1 (BRCA OR heredit* OR inherit* OR genet* OR familial* OR mutat*):ti,ab,kw #2 MeSH descriptor: [Breast Neoplasms] explode all trees #3 (breast):ti,ab,kw #4 (cancer OR carcinoma OR tumor OR tumour):ti,ab,kw #5 #3 AND #4 #6 #2 OR #5 #7 #1 AND #6 #8 (Polymerase):ti,ab,kw OR PARP:ti,ab,kw #9 neoadjuvant:ti,ab,kw #10 #7 AND #8 AND #9 #11 #10 with Cochrane Library publication date from Jan 2020 to present, in Cochrane Reviews #12 #10 with Publication Year from 2019 to 2023, in Trials | Cochrane | |
| ((((遺伝性乳癌卵巣癌症候群/TH) or (((乳房腫瘍/TH or 乳癌/AL)) and ((遺伝性/AL) or (HBOC/AL) or (BRCA/AL)))) and ((“Poly (ADP-Ribose) Polymerase-1″/TH) or (PARP/TA)))) and (DT=2020:2023 and PT=会議録除く) | 医中誌 | |
| FQ1 | (“brca*”[Text Word] OR “hereditary breast”[Text Word] OR ((“heredit*”[Text Word] OR “inherit*”[Text Word] OR “genet*”[Text Word] OR “familial*”[Text Word] OR “mutat*”[Text Word]) AND (“breast cancer”[Text Word] OR “breast neoplasms”[MeSH Terms]))) AND (“Platinum Compounds”[MeSH Terms] OR (“platinum”[Text Word] OR “carboplatin”[Text Word] OR “cisplatin”[Text Word])) AND (“Neoadjuvant Therapy”[MeSH Terms] OR “neoadjuvant”[Text Word]) AND (“English”[Language] OR “Japanese”[Language]) AND 2020/01/01:2023/03/31[Date – Publication] | PubMed |
| #1 (BRCA OR heredit* OR inherit* OR genet* OR familial* OR mutat*):ti,ab,kw #2 MeSH descriptor: [Breast Neoplasms] explode all trees #3 (breast):ti,ab,kw #4 (cancer OR carcinoma OR tumor OR tumour):ti,ab,kw #5 #3 AND #4 #6 #2 OR #5 #7 #1 AND #6 #8 (platinum):ti,ab,kw OR (cisplatin):ti,ab,kw #9 neoadjuvant:ti,ab,kw #10 #7 AND #8 AND #9 #11 #10 with Cochrane Library publication date from Jan 2020 to present, in Cochrane Reviews #12 #10 with Publication Year from 2019 to 2023, in Trials | Cochrane | |
| ((((遺伝性乳癌卵巣癌症候群/TH) or (((乳房腫瘍/TH or 乳癌/AL)) and ((遺伝性/AL) or (HBOC/AL) or (BRCA/AL)))) and (((白金/TH or プラチナ/AL)) or (platinum/TA)))) and (DT=2020:2023 and PT=会議録除く) | 医中誌 | |
| FQ2 | (((BRCA*[TW] OR hereditary breast[TW] OR ((heredit*[TW] OR inherit*[TW] OR genet*[TW] OR familial*[TW] OR mutat*[TW]) AND (breast cancer[TW] OR Breast Neoplasms[MeSH]))) AND (tamoxifen[TW])) AND ((“Chemoprevention”[Mesh] OR chemoprevent*[TW]) OR (prevent*[TW]))) AND (English[LA] OR Japanese[LA]) AND 2020[DP] : 2023/03[DP] | PubMed |
| #1 (BRCA OR heredit* OR inherit* OR genet* OR familial* OR mutat*):ti,ab,kw #2 MeSH descriptor: [Breast Neoplasms] explode all trees #3 (breast):ti,ab,kw #4 (cancer OR carcinoma OR tumor OR tumour):ti,ab,kw #5 #3 AND #4 #6 #2 OR #5 #7 #1 AND #6 #8 (chemoprevent*):ti,ab,kw OR (tamoxifen):ti,ab,kw #9 #7 AND #8 #10 #9 with Cochrane Library publication date from Jan 2020 to present, in Cochrane Reviews #11 #9 with Publication Year from 2019 to 2023, in Trials | Cochrane | |
| ((((遺伝性乳癌卵巣癌症候群/TH) or (((乳房腫瘍/TH or 乳癌/AL)) and ((遺伝性/AL) or (HBOC/AL) or (BRCA/AL)))) and ((化学予防/TH or 化学予防/AL)))) and (DT=2020:2023 and PT=会議録除く) | 医中誌 | |
| FQ3 | ((BRCA*[TW] OR hereditary breast[TW] OR ((heredit*[TW] OR inherit*[TW] OR genet*[TW] OR familial*[TW] OR mutat*[TW]) AND (breast cancer[TW] OR Breast Neoplasms[MeSH]))) AND ((“Breast Self-Examination”[TW]) OR ( awareness[TW]))) AND (English[LA] OR Japanese[LA]) AND 2020[DP] : 2023/03[DP] | PubMed |
| #1 (BRCA OR heredit* OR inherit* OR genet* OR familial* OR mutat*):ti,ab,kw #2 MeSH descriptor: [Breast Neoplasms] explode all trees #3 (breast):ti,ab,kw #4 (cancer OR carcinoma OR tumor OR tumour):ti,ab,kw #5 #3 AND #4 #6 #2 OR #5 #7 #1 AND #6 #8 (self-exam*):ti,ab,kw OR awareness #9 #7 AND #8 #10 #9 with Cochrane Library publication date from Jan 2020 to present, in Cochrane Reviews #11 #9 with Publication Year from 2019 to 2023, in Trials | Cochrane | |
| (((“breast awareness”/AL or ブレストアウェアネス/AL or ブレスト・アウェアネス/AL) or (((遺伝性乳癌卵巣癌症候群/TH) or (((乳房腫瘍/TH or 乳癌/AL)) and ((遺伝性/AL) or (HBOC/AL) or (BRCA/AL)))) and ((触診/TH or 触診/AL))))) and (DT=2020:2023 and PT=会議録除く) | 医中誌 | |
| FQ4 | (((BRCA*[TW] OR hereditary breast[TW] OR ((heredit*[TW] OR inherit*[TW] OR genet*[TW] OR familial*[TW] OR mutat*[TW]) AND (breast cancer[TW] OR Breast Neoplasms[MeSH]))) AND ((mastectomy[TW]) OR (surgery[TW])) AND ((risk-reducing[TW]) OR (prophylactic[TW]))) AND ((“Specimen Handling”[Mesh]) OR (occult[TW]) OR (Breast/pathology[MH] OR Breast Neoplasms/pathology[MH]))) AND (English[LA] OR Japanese[LA]) AND 2020[DP] : 2023/03[DP] | PubMed |
| #1 (BRCA OR heredit* OR inherit* OR genet* OR familial* OR mutat*):ti,ab,kw #2 MeSH descriptor: [Breast Neoplasms] explode all trees #3 (breast):ti,ab,kw #4 (cancer OR carcinoma OR tumor OR tumour):ti,ab,kw #5 #3 AND #4 #6 #2 OR #5 #7 #1 AND #6 #8 (pathology):ti,ab,kw OR specimen:ti,ab,kw #9 mastectomy:ti,ab,kw OR surgery:ti,ab,kw OR risk-reducing:ti,ab,kw OR prophylactic:ti,ab,kw OR RRM:ti,ab,kw #10 #7 AND #8 AND #9 #11 #10 with Cochrane Library publication date from Jan 2020 to present, in Cochrane Reviews #12 #10 with Publication Year from 2019 to 2023, in Trials | Cochrane | |
| (((((((遺伝性乳癌卵巣癌症候群/TH) or (((乳房腫瘍/TH or 乳癌/AL)) and ((遺伝性/AL) or (HBOC/AL) or (BRCA/AL)))) and ((乳房切除術/TH or 乳房切除/AL)))) and (SH=病理学)) or ((((遺伝性乳癌卵巣癌症候群/TH) or (((乳房腫瘍/TH or 乳癌/AL)) and ((遺伝性/AL) or (HBOC/AL) or (BRCA/AL)))) and ((乳房切除術/TH or 乳房切除/AL))) and (病理学/TH or 病理/TA)))) and (DT=2020:2023 and PT=会議録除く) | 医中誌 | |
| FQ5 | (((“brca*”[Text Word] OR “hereditary breast”[Text Word]) OR (((((“heredit*”[Text Word] OR “inherit*”[Text Word]) OR “genet*”[Text Word]) OR “familial*”[Text Word]) OR “mutat*”[Text Word]) AND (“breast cancer”[Text Word] OR “breast neoplasms”[MeSH Terms]))) AND ((“breast neoplasms, male”[MeSH Terms] OR “male breast cancer”[Text Word]) OR “male”[Title])) AND (“English”[Language] OR “Japanese”[Language]) AND 2020:2023/3/31[Date – Publication] | PubMed |
| #1 (BRCA OR heredit* OR inherit* OR genet* OR familial* OR mutat*):ti,ab,kw #2 MeSH descriptor: [Breast Neoplasms] explode all trees #3 (breast):ti,ab,kw #4 (cancer OR carcinoma OR tumor OR tumour):ti,ab,kw #5 #3 AND #4 #6 #2 OR #5 #7 #1 AND #6 #8 (male or man or med):ti,ab,kw #9 #7 AND #8 #10 (screening or surveillance):ti,ab,kw OR (risk-reducing):ti,ab,kw OR (prophylactic):ti,ab,kw #11 #9 AND #10 #12 #11 with Cochrane Library publication date from Jan 2020 to present, in Cochrane Reviews #13 #11 with Publication Year from 2019 to 2023, in Trials | Cochrane | |
| ((((((遺伝性乳癌卵巣癌症候群/TH) or (((乳房腫瘍/TH or 乳癌/AL)) and ((遺伝性/AL) or (HBOC/AL) or (BRCA/AL))))) and (CK=男)) or (((遺伝性乳癌卵巣癌症候群/TH) or (((乳房腫瘍/TH or 乳癌/AL)) and ((遺伝性/AL) or (HBOC/AL) or (BRCA/AL)))) and ((乳房腫瘍-男性/TH or 男性乳癌/AL))))) and (DT=2020:2023 and PT=会議録除く) | 医中誌 | |
| FQ6 | (“brca*”[Text Word] OR “hereditary breast”[Text Word] OR ((“heredit*”[Text Word] OR “inherit*”[Text Word] OR “genet*”[Text Word] OR “familial*”[Text Word] OR “mutat*”[Text Word]) AND (“breast cancer”[Text Word] OR “breast neoplasms”[MeSH Terms]))) AND (“reproductive techniques, assisted”[MeSH Terms] OR “cryopreservation”[Text Word] OR “fertility”[Text Word]) AND (“English”[Language] OR “Japanese”[Language]) AND 2020/01/01:2023/03/31[Date – Publication] | PubMed |
| #1 (BRCA OR heredit* OR inherit* OR genet* OR familial* OR mutat*):ti,ab,kw #2 MeSH descriptor: [Breast Neoplasms] explode all trees #3 (breast):ti,ab,kw #4 (cancer OR carcinoma OR tumor OR tumour):ti,ab,kw #5 #3 AND #4 #6 #2 OR #5 #7 #1 AND #6 #8 (reproduct* OR cryopreserv* or fertility or ovum or egg*):ti,ab,kw #9 #7 AND #8 #10 #9 with Cochrane Library publication date from Jan 2020 to present, in Cochrane Reviews #11 #9 with Publication Year from 2019 to 2023, in Trials | Cochrane | |
| ((((遺伝性乳癌卵巣癌症候群/TH) or (((乳房腫瘍/TH or 乳癌/AL)) and ((遺伝性/AL) or (HBOC/AL) or (BRCA/AL)))) and ((卵/TH) or (受精卵/AL) or (生殖補助技術/TH) or (妊孕性/AL)))) and (DT=2020:2023 and PT=会議録除く) | 医中誌 |
| 新CQ番号 | 検索式 | 検索DB |
|---|---|---|
| CQ1 | ((“Breast Neoplasms/genetics”[Mesh] OR “Ovarian Neoplasms/genetics”[Mesh]) AND (“Genes, BRCA1″[Mesh] OR “Genes, BRCA2″[Mesh] OR “BRCA1 Protein”[Mesh] OR “BRCA2 Protein”[Mesh] OR “Genetic Counseling”[Mesh]) AND (“Salpingo-oophorectomy”[Mesh] OR ((“Salpingectomy”[Mesh] OR “Fallopian Tubes/surgery”[Mesh]) AND “Ovariectomy”[Mesh]))) OR (BRCA*[TIAB] AND (RRSO[TI] OR “Salpingo-oophorectom*”[TI]) AND risk*[TIAB]) | PubMed |
| #1 BRCA*:ti #2 RRSO:ti OR “Salpingo-oophorectomy”:ti #3 #1 AND #2 #4 #3 CDSR #5 #3 CCRCT | Cochrane | |
| ((乳房腫瘍/TH or 卵巣腫瘍/TH) and (BRCA1遺伝子/TH or BRCA2遺伝子/TH or “BRCA1 Protein”/TH or “BRCA2 Protein”/TH or 遺伝相談/TH) and (卵管卵巣摘出術/TH or (卵管切除術/TH and 卵巣摘出術/TH))) or ((卵管卵巣摘出/TA or 卵巣卵管摘出/TA or 卵管卵巣切除/TA or 卵巣卵管切除/TA or RRSO/TA) and BRCA/TA and リスク/TA) | 医中誌 | |
| CQ2 | ((“Fallopian Tube Diseases/pathology”[Mesh] OR “Fallopian Tubes/pathology”[Mesh] OR “Hereditary Breast and Ovarian Cancer Syndrome/pathology”[Mesh]) AND (“Genes, BRCA1″[Mesh] OR “Genes, BRCA2″[Mesh] OR “BRCA1 Protein”[Mesh] OR “BRCA2 Protein”[Mesh] OR “Mutation”[Mesh]) AND (“Salpingo-oophorectomy”[Mesh] OR “Salpingectomy”[Mesh] OR “Ovariectomy”[Mesh]) OR (“Fallopian Tube*”[TIAB] AND patholog*[TIAB] AND (“SEE-FIM”[TIAB] OR “SEE-END”[TIAB] OR Occult[TIAB] OR SEIC[TIAB] OR (sectioning[TIAB] AND extensively[TIAB] AND examining[TIAB]))) | PubMed |
| #1 ”Fallopian Tube”:ti,ab,kw #2 RRSO:ti OR “Salpingo-oophorectomy”:ti #3 diagnos*:ti,ab,kw OR patholog*:ti,ab,kw OR “SEE-FIM”:ti,ab,kw OR “SEE-END”:ti,ab,kw OR Occult:ti,ab,kw OR SEIC:ti,ab,kw #4 #1 AND #2 AND #3 #5 #4 CDSR #6 #4 CCRCT | Cochrane | |
| (((卵管疾患;病理学/TH or 卵管;病理学/TH or ((卵管疾患/TH or 卵管/TH) and 上皮内癌/TH and “嚢胞腺癌-漿液性”/TH)) and (BRCA1遺伝子/TH or BRCA2遺伝子/TH or “BRCA1 Protein”/TH or “BRCA2 Protein”/TH) and (卵管卵巣摘出術/TH or 卵管切除術/TH or 卵巣摘出術/TH)) or ((卵管卵巣摘出/TA or 卵巣卵管摘出/TA or 卵管卵巣切除/TA or 卵巣卵管切除/TA or RRSO/TA) and (“SEE-FIM”/TA or “SEE-END”/TA or 病理/TI or オカルト癌/TA or 漿液性卵管上皮内癌/TA)) | 医中誌 | |
| CQ3 | ((“Ovarian Neoplasms/drug therapy”[Mesh] OR (“Ovarian Neoplasms/therapy”[Mesh] AND “Antineoplastic Protocols”[Mesh])) AND (“Genes, BRCA1″[Mesh] OR “Genes, BRCA2″[Mesh] OR “BRCA1 Protein”[Mesh] OR “BRCA2 Protein”[Mesh])) OR (ovar*[TI] AND (cancer*[TI] OR neoplasm*[TI]) AND BRCA*[TI] AND (chemotherap*[TIAB] OR “drug therap*”[TIAB] OR platinum*[TIAB])) | PubMed |
| #1 ovar*:ti AND (cancer*:ti OR neoplasm*:ti) #2 BRCA*:ti #3 chemotherap*:ti OR “drug therap*”:ti OR platinum*:ti #4 #1 AND #2 AND #3 #5 #4 CDSR #6 #4 CCRCT | Cochrane | |
| ((卵巣腫瘍;薬物療法/TH or (卵巣腫瘍/TH and 抗腫瘍プロトコール/TH)) and (BRCA1遺伝子/TH or BRCA2遺伝子/TH or “BRCA1 Protein”/TH or “BRCA2 Protein”/TH)) or ((卵巣癌/TA or 卵巣腫瘍/TA) and BRCA/TA and (プラチナ製剤併用/TA or プラチナ併用/TA or レジメン/TA)) | 医中誌 | |
| CQ4 | ((“Ovarian Neoplasms/drug therapy”[Mesh] OR (“Ovarian Neoplasms/therapy”[Mesh] AND “Drug Therapy”[Mesh])) AND (“Genes, BRCA1″[Mesh] OR “Genes, BRCA2″[Mesh] OR “BRCA1 Protein”[Mesh] OR “BRCA2 Protein”[Mesh]) AND (“Poly(ADP-ribose) Polymerase Inhibitors”[Mesh] OR “Poly(ADP-ribose) Polymerase Inhibitors”[Pharmacological Action])) OR (ovar*[TI] AND (cancer*[TI] OR neoplasm*[TI]) AND BRCA*[TIAB] AND (chemotherap*[TIAB] OR “drug therap*”[TIAB]) AND (PARP*[TIAB] OR “poly adp ribose polymerase inhibitor*”[TW])) | PubMed |
| #1 ovar*:ti AND (cancer*:ti OR neoplasm*:ti) #2 BRCA*:ti #3 PARP*:ti OR “poly adp ribose polymerase inhibitor”:ti #4 #1 AND #2 AND #3 #5 #4 CDSR #6 #4 CCRCT | Cochrane | |
| ((卵巣腫瘍;薬物療法/TH or (卵巣腫瘍/TH and 薬物療法/TH)) and (BRCA1遺伝子/TH or BRCA2遺伝子/TH or “BRCA1 Protein”/TH or “BRCA2 Protein”/TH) and (“Poly(ADP-Ribose) Polymerase Inhibitors”/TH or 寛解維持療法/TH)) or ((卵巣癌/TI or 卵巣腫瘍/TI) and 薬物療法/TA and BRCA/TA and (PARPインヒビタ/TA or PARP阻害/TA or 維持療法/TA)) | 医中誌 | |
| CQ5 | (“Ovarian Neoplasms”[Mesh] AND (“Genes, BRCA1″[Mesh] OR “Genes, BRCA2″[Mesh] OR “BRCA1 Protein”[Mesh] OR “BRCA2 Protein”[Mesh]) AND (“Contraceptive Agents”[Mesh] OR “Contraceptive Agents”[Pharmacological Action] OR ((“Estrogens”[Mesh] OR “Estrogens”[PA]) AND (“Progestins”[Mesh] OR “Progestins”[PA])))) OR ((“ovarian cancer*”[TIAB] OR “ovarian neoplasm*”[TIAB]) AND BRCA*[TIAB] AND (“Oral Contraceptive*”[TIAB] OR LEP[TIAB] OR (Estrogen*[TIAB] AND Progestin*[TIAB]))) | PubMed |
| #1 ovar*:ti,ab,kw AND (cancer*:ti,ab,kw OR neoplasm*:ti,ab,kw) #2 BRCA*:ti,ab,kw #3 Contraceptive*:ti OR LEP:ti OR (Estrogen*:ti AND Progestin*:ti) #4 #1 AND #2 AND #3 #5 #2 AND #3 #6 #5 CDSR #7 #5 CCRCT | Cochrane | |
| (卵巣腫瘍/TH and (BRCA1遺伝子/TH or BRCA2遺伝子/TH or “BRCA1 Protein”/TH or “BRCA2 Protein”/TH) and (避妊剤/TH or (Estrogens/TH and Progestins/TH))) or ((卵巣癌/TI or 卵巣腫瘍/TI) and BRCA/TA and (避妊剤/TA or 避妊薬/TA or ((Estrogens/TA or エストロゲン/TA) and (Progestins/TA or プロゲスチン/TA)) or LEP/TA)) | 医中誌 | |
| CQ6 | (“Breast Neoplasms”[Mesh] AND (“Genes, BRCA1″[Mesh] OR “Genes, BRCA2″[Mesh] OR “BRCA1 Protein”[Mesh] OR “BRCA2 Protein”[Mesh]) AND “Hormone Replacement Therapy”[Mesh]) OR ((“breast cancer*”[TIAB] OR “breast neoplasm*”[TIAB]) AND BRCA*[TIAB] AND (“Hormone replacement therapy”[TIAB] OR HRT[TIAB])) | PubMed |
| #1 breast:ti,ab,kw AND (cancer*:ti,ab,kw OR neoplasm*:ti,ab,kw) #2 BRCA*:ti #3 “Hormone replacement therapy”:ti,ab,kw OR HRT:ti,ab,kw #4 #1 AND #2 AND #3 #5 #4 CDSR #6 #4 CCRCT | Cochrane | |
| (乳房腫瘍/TH and (BRCA1遺伝子/TH or BRCA2遺伝子/TH or “BRCA1 Protein”/TH or “BRCA2 Protein”/TH) and ホルモン補充療法/TH) or ((乳癌/TI or 乳房腫瘍/TI) and BRCA/TA and (ホルモン補充療法/TA or ホルモン代償療法/TA or エストロゲン補充療法/TA or エストロゲン代償療法/TA or HRT/TA)) | 医中誌 | |
| FQ1 | ((“Salpingo-oophorectomy”[Mesh] OR “Salpingectomy”[Mesh] OR “Ovariectomy”[Mesh]) AND (“Peritoneal Neoplasms/diagnosis”[Mesh] OR “Peritoneal Neoplasms/genetics”[Mesh] OR “Peritoneal Neoplasms/epidemiology”[Mesh]) AND (“Diagnostic Techniques and Procedures”[Mesh] OR “Genotype”[Mesh] OR “Biomarkers, Tumor”[Mesh] OR “Genotyping Techniques”[Mesh])) OR ((RRSO[TIAB] OR “Salpingo-oophorectom*”[TIAB]) AND (“peritoneal cancer*”[TIAB] OR “peritoneal carcinoma*”[TIAB] OR “peritoneal neoplasm*”[TIAB]) AND (diagnos*[TIAB] OR surveillance[TIAB] OR CA125[TIAB] OR “CA 125″[TIAB] OR imaging[TIAB] OR ultrasound[TIAB] OR CT[TI] OR “Computed Tomography”[TIAB])) | PubMed |
| #1 RRS*:ti OR “Salpingo-oophorectomy”:ti #2 peritoneal cancer”:ti,ab,kw OR “peritoneal carcinoma”:ti,ab,kw OR “peritoneal neoplasm”:ti,ab,kw #3 diagnosis:ti,ab,kw OR surveillance:ti,ab,kw OR CA125:ti,ab,kw OR “CA 125”:ti,ab,kw OR imaging:ti,ab,kw OR ultrasound:ti,ab,kw OR CT:ti OR “Computed Tomography”:ti,ab,kw #4 #1 AND #2 AND #3 #5 #4 CDSR #6 #4 CCRCT | Cochrane | |
| ((卵管卵巣摘出術/TH or 卵管切除術/TH or 卵巣摘出術/TH) and 腹膜腫瘍/TH and (診断技術と処置/TH or 遺伝子型/TH or 遺伝子型判定法/TH or 腫瘍バイオマーカー/TH)) or ((卵管卵巣摘出/TA or 卵巣卵管摘出/TA or 卵管卵巣切除/TA or 卵巣卵管切除/TA or RRSO/TA) and (腹膜腫瘍/TA or 腹膜癌/TA) and (サーベイランス/TA or CA125/TA or “CQ-125″/TA or 遺伝子型/TA or 画像診断/TA or 超音波検査/TA or CT/TI or “PET-CT”/TA or 腫瘍バイオマーカー/TA)) | 医中誌 | |
| FQ2 | (“Ovarian Neoplasms/therapy”[Mesh] AND (“Genes, BRCA1″[Mesh] OR “Genes, BRCA2″[Mesh] OR “BRCA1 Protein”[Mesh] OR “BRCA2 Protein”[Mesh]) AND (“Fertility Preservation”[Mesh] OR “Fertility”[Mesh] OR “Pregnancy”[Mesh] OR “Pregnancy Rate”[Mesh] OR “Organ Sparing Treatments”[Mesh])) OR ((“ovarian cancer*”[TIAB] OR “ovarian metastasis”[TIAB]) AND (“Fertility preservation”[TI] OR “fertility sparing”[TI] OR “ovarian function”[TI] OR “ovarian tissue cryopreservation”[TI] OR “pregnancy outcome”[TI] OR Oncofertility[TI]) AND (surg*[TIAB] OR chemotherapy[TIAB] OR oncotherapy[TIAB])) | PubMed |
| #1 ovar*:ti,ab,kw AND (cancer*:ti,ab,kw OR neoplasm*:ti,ab,kw) #2 BRCA*:ti,ab,kw #3 “Fertility preservation”:ti OR “fertility sparing”:ti OR “ovarian function”:ti OR “ovarian tissue cryopreservation”:ti OR “pregnancy outcome”:ti OR Oncofertility:ti #4 #1 AND #2 AND #3 #5 #4 CDSR #6 #4 CCRCT | Cochrane | |
| (卵巣腫瘍/TH and (BRCA1遺伝子/TH or BRCA2遺伝子/TH or “BRCA1 Protein”/TH or “BRCA2 Protein”/TH) and (妊孕性温存/TH or 生殖能力/TH or 妊娠/TH or 妊娠率/TH or 臓器温存治療/TH)) or ((卵巣癌/TA or 卵巣腫瘍/TA) and BRCA/TA and (妊孕性温存/TA or 妊娠/TA or 卵巣機能/TA)) | 医中誌 | |
| FQ3 | ((“Ovarian Neoplasms/therapy”[Mesh] OR “Fallopian Tube Neoplasms/therapy”[Mesh]) AND (“Genes, BRCA1″[Mesh] OR “Genes, BRCA2″[Mesh] OR “BRCA1 Protein”[Mesh] OR “BRCA2 Protein”[Mesh] OR “Genetic Predisposition to Disease”[Mesh]) AND (“Salpingo-oophorectomy”[Mesh] OR (“Salpingectomy”[Mesh] AND “Ovariectomy”[Mesh]))) OR ((RRS[TI] OR “Salpingo-oophorectom*”[TI] OR “Opportunistic salpingectom*”[TI]) AND “ovarian cancer*”[TI] AND (BRCA*[TIAB] OR counselling[TIAB] OR prevent*[TI])) | PubMed |
| #1 ovar*:ti,ab,kw AND (cancer*:ti,ab,kw OR neoplasm*:ti,ab,kw) #2 RRS*:ti OR “Salpingo-oophorectomy”:ti OR “Opportunistic salpingectomy”:ti #3 BRCA*:ti #4 #1 AND #2 AND #3 #5 #4 CDSR #6 #4 CCRCT | Cochrane | |
| ((卵巣腫瘍/TH or 卵管腫瘍/TH) and (BRCA1遺伝子/TH or BRCA2遺伝子/TH or “BRCA1 Protein”/TH or “BRCA2 Protein”/TH) and (卵管卵巣摘出術/TH or (卵管切除術/TH and 卵巣摘出術/TH))) or ((卵巣癌/TA or 卵巣腫瘍/TA) and BRCA/TA and (卵管卵巣摘出/TA or 卵巣卵管摘出/TA or 卵管卵巣切除/TA or 卵巣卵管切除/TA or RRS/TA)) | 医中誌 | |
| FQ4 | ((“Ovarian Neoplasms/pathology”[Mesh] OR “Cytodiagnosis”[Mesh]) AND (“Genes, BRCA1″[Mesh] OR “Genes, BRCA2″[Mesh] OR “BRCA1 Protein”[Mesh] OR “BRCA2 Protein”[Mesh] OR “Tumor Suppressor Protein p53/genetics”[Mesh] OR “Mutation”[Mesh]) AND (“Salpingo-oophorectomy”[Mesh] OR “Salpingectomy”[Mesh] OR “Ovariectomy”[Mesh])) OR (BRCA*[TIAB] AND (RRSO[TI] OR “Salpingo-oophorectom*”[TI]) AND (patholog*[TW] OR cytodiagnosis[TIAB] OR cytology[TIAB] OR Occult[TIAB] OR SEIC[TIAB] OR “p53 signature”[TIAB]) AND (risk*[TIAB] OR therap*[TIAB] OR treatment[TIAB] OR prevent*[TIAB])) | PubMed |
| #1 RRS*:ti OR “Salpingo-oophorectomy”:ti #2 BRCA*:ti,ab,kw #3 patholog*:ti,ab,kw OR cytodiagnosis:ti,ab,kw OR cytology:ti,ab,kw OR Occult:ti,ab,kw OR SEIC:ti,ab,kw OR “p53 signature”:ti,ab,kw #4 #1 AND #2 AND #3 #5 #4 CDSR #6 #4 CCRCT | Cochrane | |
| ((卵巣腫瘍;病理学/TH or 病理学/TH or “腫瘍抑制タンパク質p53″/TH or (上皮内癌/TH and “嚢胞腺癌-漿液性”/TH)) and (BRCA1遺伝子/TH or BRCA2遺伝子/TH or “BRCA1 Protein”/TH or “BRCA2 Protein”/TH) and (卵管卵巣摘出術/TH or 卵管切除術/TH or 卵巣摘出術/TH)) or ((卵管卵巣摘出/TA or 卵巣卵管摘出/TA or 卵管卵巣切除/TA or 卵巣卵管切除/TA or RRSO/TA) and (病理/TI or 細胞診/TA or オカルト癌/TA or 漿液性卵管上皮内癌/TA or p53シグネチャ/TA)) | 医中誌 |
| 新CQ番号 | 検索式 | 検索DB |
|---|---|---|
| CQ1 | (((((“brca*”[Text Word] OR ((“germ-line mutation”[MeSH Terms] OR “germline”[Title/Abstract]) OR “germ-line”[Title/Abstract])) OR “neoplastic syndromes, hereditary”[MeSH Terms]) AND (“prostate cancer”[Title/Abstract] OR “prostatic neoplasms”[MeSH Terms])) AND (((“prostate-specific antigen”[MeSH Terms] OR “psa”[Title/Abstract]) OR “magnetic resonance imaging”[MeSH Terms]) OR (“surveillance”[Title/Abstract] OR “screening”[Title/Abstract]))) AND (“English”[Language] OR “Japanese”[Language])) AND 2020:2023/3/31[Date – Publication] | PubMed |
| #1 (BRCA OR heredit* OR inherit* OR genet* OR familial* OR mutat*):ti,ab,kw #2 MeSH descriptor: [Prostatic Neoplasms] explode all trees #3 (prostate):ti,ab,kw #4 (cancer OR carcinoma OR tumor OR tumour):ti,ab,kw #5 #3 AND #4 #6 #2 or #5 #7 #1 and #6 #8 (‘prostate-specific antigen’ or PSA):ti,ab,kw #9 (‘magnetic resonance imaging’ or MRI):ti,ab,kw #10 (surveillance or screening):ti,ab,kw #11 #8 or #9 or #10 #12 #7 and #11 #13 #12 with Cochrane Library publication date from Jan 2020 to present, in Cochrane Reviews #14 #12 with Publication Year from 2019 to 2023, in Trials | Cochrane | |
| ((((遺伝性乳癌卵巣癌症候群/TA or (腫瘍症候群-遺伝性/TH or 遺伝性腫瘍症候群/AL) or HBOC/TA or BRCA/AL or 生殖細胞系列変異/TH) and (前立腺腫瘍/TH or 前立腺癌/TA)) and (((前立腺特異抗原/TH or PSA/AL)) or ((集団検診/TH or スクリーニング/AL)) or ((集団サーベイランス/TH or サーベイランス/AL))))) and (DT=2020:2023 and PT=会議録除く) | 医中誌 | |
| FQ1 | ((“brca*”[Text Word] OR ((“germ-line mutation”[MeSH Terms] OR “germline”[Title/Abstract]) OR “germ-line”[Title/Abstract])) OR “neoplastic syndromes, hereditary”[MeSH Terms]) AND (“prostate cancer”[Title/Abstract] OR “prostatic neoplasms”[MeSH Terms]) AND (“Therapeutics”[MeSH Terms] OR “therapy”[MeSH Subheading]OR “pathology”[MeSH Subheading]) AND (“English”[Language] OR “Japanese”[Language]) AND 2020:2023/3/31[Date – Publication] | PubMed |
|
#1 (BRCA OR heredit* OR inherit* OR genet* OR familial* OR mutat*):ti,ab,kw #2 MeSH descriptor: [Prostatic Neoplasms] explode all trees #3 (prostate):ti,ab,kw #4 (cancer OR carcinoma OR tumor OR tumour):ti,ab,kw #5 #3 AND #4 #6 #2 or #5 #7 #1 and #6 #8 MeSH descriptor: [Therapeutics] explode all trees #9 (therapy or treatment or chemotherapy):ti,ab,kw #10 #8 or #9 #11 #7 and #10 #12 #11 with Cochrane Library publication date from Jan 2020 to present, in Cochrane Reviews #13 #11 with Publication Year from 2019 to 2023, in Trials | Cochrane | |
| (((((遺伝性乳癌卵巣癌症候群/TA or (腫瘍症候群-遺伝性/TH or 遺伝性腫瘍症候群/AL) or HBOC/TA or BRCA/AL or 生殖細胞系列変異/TH) and (前立腺腫瘍/TH or 前立腺癌/TA))) and (DT=2020:2023 and PT=会議録除く))) and (SH=治療的利用,治療,薬物療法,外科的療法,移植,食事療法,精神療法,放射線療法) | 医中誌 |
| 新CQ番号 | 検索式 | 検索DB |
|---|---|---|
| CQ1 | (((“Pancreatic Neoplasms”[MeSH Terms] OR “pancreatic cancer”[Title/Abstract]) AND (“brca*”[Text Word] OR “Mutation”[Text Word] OR “neoplastic syndromes, hereditary”[MeSH Terms])) OR “pancreatic neoplasms/genetics”[MeSH Terms]) AND (“poly adp ribose polymerase inhibitors”[MeSH Terms] OR “poly adp ribose polymerase inhibitors”[Pharmacological Action] OR “folfirinox”[Text Word] OR “olaparib”[Text Word] OR “platinum”[Text Word]) AND (“English”[Language] OR “Japanese”[Language]) AND 2020/01/01:2023/03/31[Date – Publication] | PubMed |
|
#1 (BRCA OR heredit* OR inherit* OR genet* OR familial* OR mutat*):ti,ab,kw #2 MeSH descriptor: [Pancreatic Neoplasms] explode all trees #3 (pancreatic):ti,ab,kw #4 (cancer OR carcinoma OR tumor OR tumour):ti,ab,kw #5 #3 AND #4 #6 #2 or #5 #7 #1 and #6 #8 MeSH descriptor: [Poly(ADP-ribose) Polymerase Inhibitors] explode all trees #9 (‘ Poly(ADP-ribose) Polymerase’):ti,ab,kw #10 (PARP or folfirinox or olaparib):ti,ab,kw #11 #8 or #9 or #10 #12 #7 and #11 #13 #7 with Cochrane Library publication date from Jan 2020 to present, in Cochrane Reviews #14 #7 with Publication Year from 2019 to 2023, in Trials | Cochrane | |
| (((((膵臓腫瘍/TH or 膵臓癌/AL)) and (遺伝性乳癌卵巣癌症候群/TA or 腫瘍症候群-遺伝性/TH or 遺伝性腫瘍症候群/AL or HBOC/TA or BRCA/AL or 変異/TH)) and (([Poly(ADP-Ribose) Polymerase Inhibitors]/TH) or (PARP/TA)))) and (DT=2020:2023 and PT=会議録除く and CK=ヒト) | 医中誌 |
